{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:20:18Z","timestamp":1787667618573,"version":"build-2736575974"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Homozygous familial hypercholesterolaemia (HoFH) is a rare and life-threatening genetic disease characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) levels, important xanthomatosis and increased risk of premature atherosclerotic cardiovascular disease. Management of HoFH at an early stage is recommended but conventional lipid-lowering therapies (LLTs) dependent on the LDL-receptor for clearance of LDL particles, are usually not sufficient. However, agents acting independently of the LDL-receptor, such as inhibitors of microsomal triglyceride transfer protein (MTP) or angiopoietin-like protein 3 (ANGPTL3), administered in combination, on top of standard-of-care LLT constitute a promising therapy for HoFH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>The present case describes a long-term (&amp;gt;10 years) follow-up of a 52-year-old woman with severe HoFH, who was treated with conventional lipid-lowering medications (i.e. statins and ezetimibe) for several years before experiencing the risks and benefits that were encountered with the use of LDL-receptor-independent agents (MTP and ANGPTL3 inhibitors). This combination therapy demonstrated a good long-term safety and efficacy profile, while continuous monitoring of hepatic enzymes (sometimes requiring dose adjustments) and fat accumulation is recommended when using lomitapide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Treating this HoFH patient with an LLT involving the combination of MTP and ANGPTL3 LDL-receptor-independent inhibitors (lomitapide and evinacumab, respectively) showed remarkable improvement in LDL-C levels, disappearance of xanthomatosis and regression in atherosclerotic plaques. In addition to safety and efficacy, one should question the affordability and access hurdle that emerging combination of expensive therapies might constitute in the future for the payers. These challenges could eventually limit the clinical use of those innovative treatments despite their clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytad029","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T17:43:25Z","timestamp":1673977405000},"source":"Crossref","is-referenced-by-count":10,"title":["Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2943-9175","authenticated-orcid":false,"given":"Etienne","family":"Khoury","sequence":"first","affiliation":[{"name":"Lipidology Unit, Community Genomic Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al and ECOGENE-21 Clinical and Translational Research Center , 930 Jacques-Cartier Est, Chicoutimi, Qu\u00e9bec , Canada G7H 7K9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Lauzi\u00e8re","sequence":"additional","affiliation":[{"name":"Lipidology Unit, Community Genomic Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al and ECOGENE-21 Clinical and Translational Research Center , 930 Jacques-Cartier Est, Chicoutimi, Qu\u00e9bec , Canada G7H 7K9"},{"name":"Lipid Clinic, Chicoutimi Hospital , Chicoutimi, Qu\u00e9bec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J","family":"Raal","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Witwatersrand , Johannesburg , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mancini","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of British Columbia , Vancouver, British Columbia , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"Lipidology Unit, Community Genomic Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al and ECOGENE-21 Clinical and Translational Research Center , 930 Jacques-Cartier Est, Chicoutimi, Qu\u00e9bec , Canada G7H 7K9"},{"name":"Lipid Clinic, Chicoutimi Hospital , Chicoutimi, Qu\u00e9bec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"2023012809212670300_ytad029-B1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MOL.0000000000000677","article-title":"Homozygous familial hypercholesterolemia: what treatments are on the horizon?","volume":"31","author":"Bajaj","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"2023012809212670300_ytad029-B2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"2023012809212670300_ytad029-B3","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J Clin Invest"},{"key":"2023012809212670300_ytad029-B4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2023012809212670300_ytad029-B5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11883-020-00858-4","article-title":"Lomitapide-a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia","volume":"22","author":"Stefanutti","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"2023012809212670300_ytad029-B6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14740338.2019.1602606","article-title":"Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia","volume":"18","author":"Khoury","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"2023012809212670300_ytad029-B7","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s12325-021-02031-y","article-title":"A case series assessing the effects of lomitapide on carotid intima-media thickness in adult patients with homozygous familial hypercholesterolaemia in a real-world setting","volume":"39","author":"Blom","year":"2022","journal-title":"Adv Ther"},{"key":"2023012809212670300_ytad029-B8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1538\/expanim.55.27","article-title":"Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity","volume":"55","author":"Fujimoto","year":"2006","journal-title":"Exp Anim"},{"key":"2023012809212670300_ytad029-B9","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"2023012809212670300_ytad029-B10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"key":"2023012809212670300_ytad029-B11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2023012809212670300_ytad029-B12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"2023012809212670300_ytad029-B13","volume-title":"FDA Drug approvals and databases","author":"Clinical review(s) of Lomitapide for treating patients with homozygous familial hypercholesterolemia","year":"2012"},{"key":"2023012809212670300_ytad029-B14","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"2023012809212670300_ytad029-B15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2020.07.028","article-title":"Lomitapide for treatment of homozygous familial hypercholesterolemia: the Quebec experience","volume":"310","author":"Aljenedil","year":"2020","journal-title":"Atherosclerosis"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytad029\/48745139\/ytad029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/7\/1\/ytad029\/48944354\/ytad029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/7\/1\/ytad029\/48944354\/ytad029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T04:22:11Z","timestamp":1674879731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytad029\/6989637"}},"subtitle":[],"editor":[{"given":"David","family":"Oxborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Georgios A","family":"Christou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Roman","family":"Komorovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Pok-Tin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Michael","family":"Waight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytad029","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,12,27]]},"article-number":"ytad029"}}